Valuation: SCYNEXIS, Inc.

Market Cap 42.4M 37.06M 34.19M 31.52M 59.41M 4.08B 60.72M 409M 161M 2B 159M 156M 6.88B P/E 2026 *
-1.05x
P/E 2027 * -1.69x
Enterprise Value 42.4M 37.06M 34.19M 31.52M 59.41M 4.08B 60.72M 409M 161M 2B 159M 156M 6.88B EV / Sales 2026 *
36.7x
EV / Sales 2027 * 6.35x
Free-Float
98%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: SCYNEXIS, Inc.

1 day-4.69%
1 week-2.51%
Current month+4.91%
1 month+5.43%
3 months-51.91%
6 months-17.88%
Current year-15.60%
1 week 4.23
Extreme 4.23
5.1
1 month 3.68
Extreme 3.68
5.1
Current year 3.68
Extreme 3.68
9.12
1 year 3.68
Extreme 3.68
10.48
3 years 3.68
Extreme 3.68
30.96
5 years 3.68
Extreme 3.68
64.8
10 years 3.68
Extreme 3.68
440.8
Manager TitleAgeSince
Chief Executive Officer 61 01/01/2023
Director of Finance/CFO 65 24/10/2022
Chief Tech/Sci/R&D Officer - 01/10/2020
Director TitleAgeSince
Director/Board Member 73 01/12/2008
Chairman 67 04/06/2015
Director/Board Member 61 01/01/2023
Date Insider Type Main position Quantity % Market Cap.
26/6/26 Free

Director

5,750 0.0579%
26/6/26 Free

Chairman

5,750 0.0579%
26/6/26 Free

Director

5,750 0.0579%
Change 5-day change 1-year change 3-year change Capi.($)
-4.69%-2.51%-26.38%-81.01% 42.4M
+0.85%-0.80%+52.79%+159.97% 1,051B
+1.23%-1.53%+54.58%+59.41% 609B
+0.04%+2.58%+34.47%+84.84% 450B
+0.78%-0.71%+29.28%+23.25% 330B
+1.41%+0.58%+35.44%+40.53% 284B
-0.27%-1.87%+22.34%+19.92% 263B
-1.76%+2.37%-20.43%-38.01% 223B
-1.42%+0.80%+24.27%+57.85% 198B
-1.48%+3.43%+24.08%+70.06% 167B
Average -0.53%+0.23%+23.04%+39.68% 357.51B
Weighted average by Cap. +0.37%+0.02%+37.51%+78.76%

Financials

2026 *2027 *
Net sales 1.15M 1.01M 931K 858K 1.62M 111M 1.65M 11.12M 4.37M 54.43M 4.33M 4.24M 187M 6.68M 5.84M 5.38M 4.96M 9.35M 643M 9.56M 64.36M 25.31M 315M 25.08M 24.53M 1.08B
Net income -41.07M -35.89M -33.12M -30.53M -57.54M -3.96B -58.82M -396M -156M -1.94B -154M -151M -6.67B -28.73M -25.11M -23.17M -21.35M -40.25M -2.77B -41.14M -277M -109M -1.36B -108M -106M -4.66B
Net Debt - -
Logo SCYNEXIS, Inc.
SCYNEXIS, Inc. is a biotechnology company focused on developing therapies to address severe rare diseases. The Company's SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. Its proprietary antifungal platform, fungerps, includes BREXAFEMME (ibrexafungerp tablets), which has been licensed to GSK, and SCY-247, which is in clinical stages of development. Its SCY-770 is a novel, highly selective, direct AMP-activated protein kinase (AMPK) activator for the treatment of ADPKD, a genetic cause of end-stage renal failure. Its SCY-770 is designed to address many of the underlying drivers of ADPKD by reducing cyst growth and disease progression. The United States Food and Drug Administration (FDA) has approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis (VVC) and for the reduction in the incidence of recurrent vulvovaginal candidiasis (rVVC).
Employees
18
Date Price Change Volume
17/07/26 US$4.270 -4.69% 22,838
16/07/26 US$4.480 -7.25% 33,685
15/07/26 US$4.830 -2.03% 35,808
14/07/26 US$4.930 +10.04% 90,803
13/07/26 US$4.480 +2.28% 47,799
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
4.270USD
Average target price
33.55USD
Spread / Average Target
+685.64%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SCYX Stock